A Phase 3 interventional study of lasofoxifene and raloxifene in Osteoporosis, sponsored by Ligand Pharmaceuticals. Completed at 72 sites in United States. Open to female participants aged 48 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-08-12.
Sponsored by Ligand Pharmaceuticals · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 481 studies in Osteoporosis with a site in United States — 26 open to participants now, 36 under way, none of them phase 3. Osteoporosis · United States.
Among the 481 studies in Osteoporosis with a site in United States, this one is the 46th largest by enrollment of the 374 interventional ones that give a count, is one of 25 that started in 2003, is one of 70 in phase 3, and was the 92nd registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →26 of the 481 studies in Osteoporosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Amber Implants B.V. · Sites in United States
Ages 21–85
University of Connecticut · Sites in United States
Ages 45–70 · Women only · Healthy volunteers
Precision IO Group · Sites in United States
Ages 22+
AO Foundation, AO Spine · Sites in United States, Argentina, Brazil and 11 more countries
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 48 Years to 75 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
481 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 93 · Phase 3 78 · Phase 4 61
First in 1985; this study’s year is marked. 25 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 540 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 73 across the 374 interventional studies, 100 across the 97 observational. Of the 405 that completed or were terminated, 154 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
112 of 481 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ligand Pharmaceuticals, one of the names counted as Ligand Pharmaceuticals Incorporated. Under that name alone:
Ligand Pharmaceuticals is the lead sponsor of 21 studies on the registry; none are open to participants now.
Ligand Pharmaceuticals Incorporated has 4 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Osteoporosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
| NCT07325578Precision IO GroupU.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures | 2027-01 |
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
| NCT07154719Pennington Biomedical Research CenterGLP-1R Actions on Muscle and the Skeleton | 2027-02-01 |
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 481 studies in Osteoporosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lasofoxifene 0.25 mg/day
Drug: lasofoxifene
raloxifene 60 mg/day
Drug: raloxifene
Placebo
Drug: Placebo
lasofoxifene 0.25mg
raloxifene 60 mg/day
0 mg/day
Spine BMD after 2 years
Lumbar Spine Bome Mineral Density
Time frame: 2 years
Hip BMD and LDL-C after 2 years, vaginal pH and Maturation Index after 1 year
Direct low density lipoprotein cholesterol (LDL-C) at 24 months, vaginal pH at 24 months, vaginal epithelial parabasal cells at 12 months, and total hip BMD at 24 months.
Time frame: Hip BMD= 24 months, LDL-C= 24 months, vaginal pH= 24 months, vaginal epithelial parabasel cells= 12 months
The record gives a start of May 2003, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lasofoxifene